Risk and management of patients with cancer and heart disease

Loreena Hill; Bruno Delgado; Ekaterini Lambrinou; Tara Mannion; Mark Harbinson; Claire McCune

doi:10.1007/s40119-023-00305-w

Risk and management of patients with cancer and heart disease

Loreena Hill
, Bruno Delgado
, Ekaterini Lambrinou
, Tara Mannion
, Mark Harbinson
, Claire McCune

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

76 Downloads (Pure)

Abstract

Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients’ functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

Original language	English
Pages (from-to)	227-241
Number of pages	15
Journal	Cardiology and Therapy
Volume	12
Issue number	2
Early online date	9 Feb 2023
DOIs	https://doi.org/10.1007/s40119-023-00305-w
Publication status	Published (in print/issue) - 1 Jun 2023

Funding

No funding or sponsorship was received for this study or the publication of this article.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Anthracycline
Cardiotoxicity
Heart failure
Risk stratification

Access to Document

10.1007/s40119-023-00305-w

s40119-023-00305-wFinal published version, 831 KBLicence: CC BY-NC

Cite this

@article{ab2af504f1ad446188b49eb3b3e63eae,

title = "Risk and management of patients with cancer and heart disease",

abstract = "Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient{\textquoteright}s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients{\textquoteright} functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.",

keywords = "Anthracycline, Cardiotoxicity, Heart failure, Risk stratification",

author = "Loreena Hill and Bruno Delgado and Ekaterini Lambrinou and Tara Mannion and Mark Harbinson and Claire McCune",

year = "2023",

month = jun,

day = "1",

doi = "10.1007/s40119-023-00305-w",

language = "English",

volume = "12",

pages = "227--241",

journal = "Cardiology and Therapy",

issn = "2193-8261",

publisher = "Adis",

number = "2",

}

TY - JOUR

T1 - Risk and management of patients with cancer and heart disease

AU - Hill, Loreena

AU - Delgado, Bruno

AU - Lambrinou, Ekaterini

AU - Mannion, Tara

AU - Harbinson, Mark

AU - McCune, Claire

PY - 2023/6/1

Y1 - 2023/6/1

N2 - Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients’ functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

AB - Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients’ functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

KW - Anthracycline

KW - Cardiotoxicity

KW - Heart failure

KW - Risk stratification

U2 - 10.1007/s40119-023-00305-w

DO - 10.1007/s40119-023-00305-w

M3 - Article

SN - 2193-8261

VL - 12

SP - 227

EP - 241

JO - Cardiology and Therapy

JF - Cardiology and Therapy

IS - 2

ER -

Risk and management of patients with cancer and heart disease

Abstract

Funding

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this